Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharm 1 > drug therapy for treatment of MG, Alzheimer's, and urinary retention > Flashcards

drug therapy for treatment of MG, Alzheimer's, and urinary retention Flashcards

1
Q

describe what happens when the parasympathetic nervous system is activated

A
  • constricts pupils
  • stimulates salivation
  • slows heart
  • constricts bronchioles
  • stimulate digestion
  • stimulates gallbladder
  • contracts bladder
  • stimulates sex organs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

describe what happens when the sympathetic nervous system is activated

A
  • dilates pupils
  • inhibits salivation
  • accelerates heart
  • dilates bronchioles
  • inhibits digestion
  • stimulates release of glucose
  • secretes epinephrine and norepinephrine
  • relaxes bladder
  • inhibits sex organs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

true or false?

direct-acting cholinergic medications readily enter the central nervous system

A

false

rationale: direct acting cholinergic medications do not readily enter the central nervous system; thus, their effects occur primarily in the periphery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

define myasthenia gravis

A

chronic autoimmune neuromuscular disease, weakness and rapid fatigue of muscles under voluntary control

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

describe the etiology of myasthenia gravis

A

defect in the transmission of nerve impulses to muscles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

describe the pathophysiology of myasthenia gravis

A

occurs when normal communication between the nerve and muscle is interrupted at the neuromuscular junction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

describe the clinical manifestations of myasthenia gravis

A
  • facial expression and swallowing, weakness of eye muscles
  • diplopia (double/burred vision)
  • dysphagia (difficulty swallowing)
  • dysarthria (slurred speech)
  • SOB
  • -*hallmark sx: symptoms increase with exertion and improve with rest
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

describe drug therapy used to treat myasthenia gravis

A
  • cholinergic drugs
  • acetylcholinesterase inhibitor drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

define neostigmine

A

used for long term treatment of myasthenia gravis and as an antidote for nondepolarizing skeletal muscle relaxants used in surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is the use of neostigmine

A

diagnosis and treatment of myasthenia gravis. reverse the action of nondepolarizing neuromuscular agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

describe the pharmacokinetics of neostigmine

A

administered slowly intravenously, metabolized by liver, excreted in the kidneys

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

describe the action of neostigmine

A
  • decreases the inactivation of acetylcholine in the synapses by the enzyme acetylcholinesterase
  • by interfering with the breakdown of Ach, stimulates both nicotinic and muscarinic receptors which are involved in muscle contraction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

describe the adverse effect of neostigmine

A
  • cardiovascular and respiratory
  • cardiac dysrhythmias, decreased cardiac output, hypotension, cardiac arrest, and respiratory depression which may indicate a cholinergic crisis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are some contraindications of neostigmine

A

hypersensitivity, lung disease, heart disease, benign prostatic hypertrophy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are some nursing implications regarding neostigmine

A
  • preventing interactions: atropine/corticosteroids (will decrease effect)
  • administerings the medication: with food/milk to decrease risk of gastric distress, ulceration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

describe assessing for therapeutic effects with neostigmine

A
  • increase in muscle strength
  • decreased difficulty with chewing, swallowing, and speech
  • absent ptosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

describe assessing for adverse effects with neostigmine

A
  • increase in central nervous system effects such as convulsions, dizziness, drowsiness, secretions, broncho and laryngospasms, and respiratory failure
  • pyridostigmine: indirectly increasing the concentration of acetylcholine at the NMJ and promoting increased cholinergic nicotinic receptor activation - has no unwanted CNS effect and does not cross blood brain barrier
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

describe pt teaching with neostigmine

A
  • educate on wearing medical alert identification device
  • rest between activities
  • increase reporting and awareness to an increase in muscle weakness
  • may have complaints of abdominal cramps, diarrhea, and difficulty breathing, these are all concerns
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

describe cholinergic crisis

A
  • occurs from an overdose of acetylcholinesterase inhibitors
  • this is an emergency, important to teach pts about the signs and symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what are the signs and symptoms of cholinergic crisis

A

extreme weakness

  • salivation
  • lacrimation
  • urinary incontinence
  • diarrhea
  • GI upset
  • emesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what is the treatment for cholinergic crisis

A
  • atropine
  • works on the muscarinic receptors (not nicotinic), so you will see changes in the heart, smooth muscles, and glands when this drug is administered to reverse or stop the cholinergic crisis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what are the characteristics of overstimulation of PNS

A

B: bronchoconstriction

A: apnea

G: gray vision

P: pupil constriction

U: urinary increase

D: diaphoresis

D: defecation

L: lacrimation

E: emesis

S: seizures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

define alzheimer’s disease

A

memory loss and loss of other intellectual abilities serious enough to interfere with daily life

24
Q

describe dementia

A
  • broad/umbrella term
  • Alzheimer’s falls under it
  • group of thinking and social symptoms that interfere with daily functioning
25
Q

describe the etiology of Alzheimer’s disease

A

most common form of dementia

26
Q

describe the pathophysiology of Alzheimer’s disease

A

deficiency in cholinergic function in the cortex and basal forebrain

27
Q

describe clinical manifestations of Alzheimers disease

A

most common early symptom is difficulty remembering newly learned information

28
Q

what different drug therapies are used to treat Alzheimer’s disease

A
  • cholinesterase inhibitors
  • n-methyl-d-aspartate receptor antagonist
  • cholinesterase inhibitor n-methyl-d-aspartate receptor antagonist
29
Q

describe the principles of cholinergic treatment of Alzheimer’s disease

A
  • goal of therapy is to slow memory and cognition loss
  • cholinergics delay progression of disease if used in early stages - brings slight improvement in cognition and function
  • other medications may be beneficial
30
Q

which medication is the most commonly used acetylcholinesterase inhibitor

A

donepezil

31
Q

define donepezil

A
  • medication that is used to inhibit acetylcholinesterase
  • permits accumulation of acetylcholine and increases stimulation of cholinergic receptors in the CNS/PNS
32
Q

describe the pharmacokinetics of donepezil

A

absorption with oral administration in good and is unaffected with food, peak of action is 3-4 hours, metabolism is in liver, excretion is mainly in the urine

33
Q

describe the action of donepezil

A

increases acetylcholine in the brain by inhibiting its metabolism

34
Q

describe the use of donepezil

A

to treat mild, moderate, or severe Alzheimer’s disease , may also be used to enhance memory is neurological conditions such as MS

35
Q

describe some adverse effects of donepezil

A
  • CNS → fatigue, seizure-like activity, lightheadedness
  • GI → increased nausea and vomiting
  • respiratory → bronchoconstriction and difficulty breathing
  • cardiovascular → decreased HR
36
Q

what are some contraindications of donepezil

A
  • hypersensitivity
  • lung disease
  • heart disease such as sick sinus syndrome (sinal node is pacemaker of the heart)
  • bradycardia, irregular HR, and cardiac history of pauses
37
Q

what are some nursing implications of donepezil

A
  • preventing interactions
  • administering the med
  • assessing for therapeutic and adverse effects
  • patient teaching
38
Q

what are some other drugs in the same class as donepezil

A

galantamine hydrobromide

rivastigmine

39
Q

define memantine

A

a n-methyl-d-aspartate (NMDA) receptor antagonist

40
Q

describe the use of memantine

A

used for patients with moderate to severe Alzheimers disease

41
Q

describe the pharmacokinetics of memantine

A

well absorbed orally, 100% absorption in GI tract, partially metabolized in the liver, excreted through the urine

42
Q

what are some contraindications of memantine

A

hypersensitivity and renal failure

43
Q

what are the adverse effects of memantine

A
  • N+V
  • dizziness
  • diarrhea and constipation
  • fatigue and body aches
44
Q

what are some nursing implications of memantine

A
  • preventing interactions
  • administering med as directed
  • assessing for therapeutic and adverse effects
  • patient teaching (report any severe side effects)
45
Q

other then atropine, what are some emergency treatments of cholinergic toxicity

A
  • decontamination (hydrate to increase fluid volume and decrease concentration)
  • activated charcoal (prevents digestion of meds in gut) and lavage
  • pharmacologic treatment
46
Q

give an overview of inhibitor n-methyl-d-aspartate receptor antagonist

A
  • combination therapy for Alzheimer’s patients
  • donepezil and meantine are a combination cholinesterase inhibitor and a NMDA
  • used in patients with moderate to severe dementia
  • assess for cardiovascular events, falls, GI upset, and overall mental status
47
Q

describe the etiology and pathophysiology of urinary retention

A
  • urinary retention may be due to sever factors:
  • neurogenic bladder (spastic and flaccid)
  • DM
  • enlarged prostate
  • pregnancy
  • MS
  • Parkinsons
  • surgery
48
Q

describe neurogenic bladder

A

any condition that impairs bladder and bladder afferent and efferent signaling from occurring - may be flaccid or spastic

49
Q

describe spastic neurogenic bladder

A
  • normal or small amount of urine, consistent involuntary contractions which results in wetting/leakage/incontinence issues
  • can result from renal or spinal cord damage, or detrusor complications
50
Q

describe flaccid neurogenic bladder

A
  • large volume of fluid in bladder
  • absence of contraction → can result from peripheral nerve damage or damage to spinal cord
51
Q

describe the clinical manifestations of urinary rentention

A
  • urinary retention or leakage
  • may have sensation of a full bladder or incomplete bladder emptying
52
Q

what type of drug therapy is used for urinary rentention

A

cholinergic agonist

53
Q

describe the pharmacokinetics of bethanechol chloride

A
  • well absorbed in GI tract
  • site of metabolism and elimination is not known
  • does not cross blood brain barrier, but does cross placenta
54
Q

describe the action of bethanechol chloride

A
  • parasympathomimetic agent
  • acts at the cholinergic receptors in the urinary and GI tracts to increase muscle tone
55
Q

describe the use of bethanechol chloride

A

nonobstructed urinary retention and neurogenic atony (loss of strength) of the bladder muscle

Pharm 1 (29 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions